Brought to you by 
AstraZeneca buys MedImmune for $15.6bn
30 Oct 2007
Executive Summary
AstraZeneca PLC has found its first entry into the vaccines market through the acquisition of MedImmune. AZ offered $58 per share for the company, a 60% premium to MedImmune's market average 10 days prior to its initial announcement in early April that it was searching for a buyer. The deal is valued at about $15.6bn.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com